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A nonsense mutation in FMR1 causing fragile X
syndrome
Karen Grønskov1, Karen Brøndum-Nielsen1,2, Alma Dedic1 and Helle Hjalgrim1,3
Fragile X syndrome is a common cause of inherited intellectual disability. It is caused by lack of the FMR1 gene product FMRP.
The most frequent cause is the expansion of a CGG repeat located in the 5¢UTR of FMR1. Alleles with 200 or more repeats
become hypermethylated and transcriptionally silent. Only few patients with intragenic point mutations in FMR1 have been
reported and, currently, routine analysis of patients referred for fragile X syndrome includes solely analysis for repeat expansion
and methylation status. We identified a substitution in exon 2 of FMR1, c.80C4A, causing a nonsense mutation p.Ser27X, in a
patient with classical clinical symptoms of fragile X syndrome. The mother who carried the mutation in heterozygous form
presented with mild intellectual impairment. We conclude that further studies including western blot and DNA sequence
analysis of the FMR1 gene should be performed in patients with typical symptoms of fragile X syndrome in whom no CGG repeat
expansion is detected.
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INTRODUCTION
Fragile X syndrome is a frequent form of inherited intellectual
disability affecting approximately 1 in 4000 males (reviewed by
Chonchaiya et al.1). In the vast majority of patients the syndrome is
caused by expansion of a CGG repeat located in the 5¢UTR of the
FMR1 gene localized to Xq27.3. The gene was cloned in 1991 and
comprises 17 coding exons. The protein, FMRP, is an RNA-binding
protein with 632 amino acids.2 Only four point mutations in FMR1
have been reported: a missense mutation p.Ile304Asn, a 1-bp deletion
c.373delA in exon 5 resulting in a frameshift and premature truncation
of the protein, a 2-bp change g.23714GG4TA spanning the intron/
exon boundary of exon 2, and a missense mutation p.Arg138Gln.3–5
Deletions of the CGG repeat and flanking sequences have been
reported several times.6
PATIENTS AND METHODS
Patient
The patient, a 35-year-old mentally retarded man, was referred to a
tertiary epilepsy centre due to difficulties in treatment of epilepsy, with
absences, generalised tonic–clonic seizures and myoclonias. On further
diagnostic evaluation he was tested for fragile X syndrome. Pheno-
typically he had classical fragile X syndrome, with an elongated face,
high, broad forehead, low-set large ears, prognathia and enlarged
testes. Neurological examination showed hypotonia and hypermobi-
lity, with hyperextensible joints. He had no active language except for a
few repeated words used out of context, and showed autistic features
with little eye contact, discomfort upon physical contact, perseveration
and limited interests. He was described by his mother as showing late
motor development in childhood and having need for speech therapy,
and special day-care and schooling. Epilepsy debuted at age 4 years.
The mother presented with mild-to-moderate intellectual disability.
She reported special education needs and carried out sheltered work.
She was married and capable of maintaining a household. Physical
examination showed a relatively unremarkable phenotype, but her
behaviour included hypermotor activity and many automatisms. She
was capable of a simple conversation.
Molecular biology procedures
Genomic DNA was extracted from peripheral blood lymphocytes
(EDTA stabilized) using standard procedures. Lymphoblastoid cell
lines were established from the patient and his mother using Epstein–
Barr virus transformation.
Southern blot analysis was performed as described.7 Briefly, 9mg of
high molecular genomic DNA was digested with Pst1, and 6mg DNA
was digested with EcoR1 plus EagI and size-separated on an agarose
gel. Standard blotting technique was used to transfer DNA to a
nitrocellulose filter, which was hybridized with radioactive labelled
pPX6 probe. After washing, the filter was analysed using a Cyclone
from Perkin-Elmer (Waltham, MA, USA).
PCR analysis of the FMR1 CGG repeat was performed using the fragile
X kit from Abbott Molecular (IL, USA) following the manufacturer’s
instructions. Western blot analysis was performed as described.7
Mutational analysis of FMR1 was performed by direct DNA
sequencing of PCR products of coding exons and at least 20 bp of
flanking sequences. Primers and PCR conditions are available upon
request. Sequencing was performed using BigDye v3.1 terminator
chemistry and an ABI3130XL genetic analyzer and using the Seqscape
program for analysis (Applied Biosystems, Foster City, CA, USA).
X-inactivation analysis was performed using the polymorphic CAG
repeat in the androgen receptor locus as described.7
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RESULTS
The patient and his mother are shown in Figure 1.
Southern blot analyses of FRAXA (EcoRI+EagI and PstI digestion,
respectively) showed band patterns corresponding to a repeat number
in the normal range (Figures 2a and b). PCR analysis showed an allele
size corresponding to 29 repeats. However, based on the classic clinical
fragile X appearance, we performed a western blot using an anti-
FMRP antibody, which showed that no FMRP was expressed
(Figure 2c and Supplementary Figure 1). We also performed Southern
blot analysis and PCR of FRAXA of the mother of the patient; this
showed a normal band pattern and repeat numbers of 29 and 33, with
no indication of a full mutation (data not shown). Subsequent DNA
sequencing revealed a sequence variation in exon 2 of FMR1 c.80C4A
resulting in a nonsense mutation p.Ser27X (Supplementary Figure 2).
Verification of the sequence variation was performed on a second PCR
product, and the variation was seen in both directions. The mother
was found to be heterozygous for the mutation. We investigated
X-inactivation pattern using a polymorphic CAG repeat in the
androgen receptor locus and found an equal distribution of active
and inactive X-chromosomes in blood (data not shown).
DISCUSSION
We report a nonsense mutation in FMR1 in a patient with classic
fragile X syndrome and his carrier mother with mild intellectual
impairment. The fragile X syndrome can be considered semi-
dominant, with manifestations of a full mutation in female
carriers, depending on the proportion of active versus inactive
X chromosomes carrying the mutation. Earlier studies have shown
that phenotypical normal females have a skewed X inactivation
pattern in favour of the inactive X carrying the mutation.8 As the
X inactivation in the mother showed an equal distribution, some
degree of intellectual impairment would be expected. However, this
study was performed in blood and therefore is an approximation, as
we do not know the pattern in brain.
Surprisingly, few point mutations have been found in the FMR1
gene. Two of these are truncating mutations in the N-terminal half of
the gene and supposedly lead to nonsense-mediated decay of the
mRNA. These two mutations caused classical fragile X syndrome.5
Another patient had a missense mutation in one of the KH domains
and had a more severe phenotype.4 This could be due to a gain-of-
function effect; however, in this family X-linked glycogenosis was also
present, which might have contributed to the phenotype. The
observed low frequency of point mutations in FMR1 might be because
FMR1 is not routinely screened for point mutations, but is only
investigated for the common CGG expansion; another reason could be
that point mutations in this gene give atypical or even lethal
phenotypes. More than 1100 patients have been screened for point
mutations in FMR1;3,9–15 however, only one missense mutation of
questionable pathogeneity was identified.3 The individuals investi-
gated in these studies represent a very heterogenous group of patients
with developmental delay, indicating that FMR1 mutations are not a
common cause for mental impairment. To our knowledge, a muta-
tional screening of FMR1 has not been performed in a large cohort of
patients with typical fragile X syndrome negative for repeat expansion.
Therefore, the frequency of point mutations in FMR1 in classical
fragile X syndrome is unknown. The patient presented in this study
shows a typical fragile X phenotype, and his mother shows a
phenotype comparable to a female with a full mutation. We therefore
suggest that in patients with clinical fragile X syndrome and no CGG
expansion expanded molecular diagnosis should be considered,
including western blot analysis and DNA sequencing.
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Figure 1 Facial appearance of (a) the patient and (b) his mother. Note the
elongated face, high broad forehead and prognathia in the patient (a).
a b c
Figure 2 Southern blot analysis using (a) EcoRI+EagI digestion and (b) PstI digestion. P, patient; M, mother; FM ~, full mutated female; PM ~, premutated
female; FM #, full mutated male; PM #, premutated male; N #, normal male; N ~, normal female. (c) Western blot analysis using an anti-FMRP antibody.
P, patient; FM #, full mutated male; N # normal male.
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